NRX Pharmaceuticals, Inc. (NRXP): Operating Income
-$16.22M
Year ended 2025-12-31
-$19.90M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$16.22M | n/m | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | -$18.50M | n/m | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | -$27.84M | n/m | 2025-03-14, From 2023-01-01 |
| 2022-12-31 | -$44.34M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | -$115.80M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$51.39M | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$713.2K | n/m | 2021-05-14, From 2019-01-01 |
| 2018-12-31 | -$1.01M | n/a | 2020-03-30, From 2018-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | -$16.22M | n/m |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | -$3.08M | n/m |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | -$59.91M | n/m |
| Cannapharmarx, Inc. (CPMD) | 2025-12-31 | -$3.35M | n/m |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | -$38.31M | n/m |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | -$7.45M | n/m |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | -$72.13M | n/m |
| Longeveron Inc. (LGVN) | 2025-12-31 | -$23.29M | n/m |
| Neuphoria Therapeutics Inc. (NEUP) | 2026-06-30 | -$16.45M | n/m |
Compare NRXP, ATXI, NWBO, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗